Claims for Patent: 9,119,839

Summary for Patent: 9,119,839

Title:	Cancer treatment
Abstract:	The present invention relates to methods of treating cancer, such as melanoma, by administering a CTLA4 antagonist to a subject with a serum C-Reactive Protein (CRP) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of serum CRP concentration in a subject, and then administering a CTLA4 antagonist if the CRP concentration is less than or equal to a certain amount. The invention further relates to, among other things, the use of serum CRP concentration as a predictive factor for a subject\'s response to a cancer treatment.
Inventor(s):	Huang; Bo (Chapel Hill, NC), Marshall; Margaret Ann (Beverly Hills, CA)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	13/860,329
Patent Claims:	1. A method for treating mesothelioma, comprising administering to a patient having mesothelioma an anti-CTLA4 antibody or an antigen-binding portion thereof as monotherapy in a multiple dose regimen, each dose having an identical dosage in the range of 1-20 mg/kg body weight, wherein the heavy chain CDR1-3 and light chain CDR1-3 of said antibody comprise the amino acid sequences set forth in a) SEQ ID NOs: 1-6, respectively; b) SEQ ID NOs: 9-14, respectively; c) SEQ ID NOs: 17-22, respectively; or d) SEQ ID NOs: 25-30, respectively. 2. The method of claim 1, wherein said dosage is a) 1 mg/kg body weight; b) 3 mg/kg body weight; c) 5 mg/kg body weight; d) 10 mg/kg body weight; e) 15 mg/kg body weight; or f) 20 mg/kg body weight. 3. The method of claim 2, wherein said anti-CTLA4 antibody or antigen-binding portion is administered: a) once per week; b) once every two weeks; c) once every three weeks; d) once every four weeks; e) once per month; f) once every three months; or g) once every three to six months. 4. The method of claim 1, wherein said anti-CTLA4 antibody or antigen-binding portion is administered at 1, 3, 5, 10, 15, or 20 mg/kg body weight every four weeks for six doses, then every three months. 5. The method of claim 1, wherein said anti-CTLA4 antibody is administered at 10 mg/kg body weight every four weeks for six doses, then every three months. 6. The method of claim 1, wherein said anti-CTLA4 antibody is administered at 15 mg/kg body weight every three months. 7. The method of claim 1, wherein said anti-CTLA4 antibody or antigen-binding portion comprises a heavy chain and a light chain comprising the amino acid sequences of: a) SEQ ID NOs: 7 and 8, respectively; b) SEQ ID NOs: 15 and 16, respectively; c) SEQ ID NOs: 23 and 24, respectively; or d) SEQ ID NOs: 31 and 32, respectively. 8. The method of claim 7, wherein said anti-CTLA4 antibody is tremelimumab. 9. The method of claim 7, wherein said anti-CTLA4 antibody is ipilimumab. 10. A method for treating mesothelioma in a patient, comprising administering tremelimumab to the patient as monotherapy at 10 mg/kg body weight every four weeks for six doses, then every three months. 11. A method for treating mesothelioma in a patient, comprising administering tremelimumab to the patient as monotherapy at 15 mg/kg body weight every three months.

Details for Patent 9,119,839

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2029-10-12